Consensus Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-1.39%		+0.71%	-86.94%

Apr. 17	Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	MT
Apr. 16	Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	MT

Evolution of the average Target Price on Marinus Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f996371afb2f275c4d7.smVEWaSSQlNFyN4StX1qt7m53HMWxUw3HJFg47pS-hY.9S9yHuv8I2UqjLho8BYa4O3JuhEuqChQXcINpP46gyTnH3cNk9hzZDPwiw~0e4a721ac5415d74d65b32b2b34395e5

Analyst Recommendations on Marinus Pharmaceuticals, Inc.

Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	Apr. 17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	Apr. 16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	Apr. 16	MT
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating	Jan. 03	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $25 From $32, Maintains Buy Rating	Nov. 08	MT
RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier	23-09-20	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $32 From $42, Maintains Buy Rating	23-08-11	MT
Ladenburg Thalmann Adjusts Price Target on Marinus Pharmaceuticals to $13 From $17, Maintains Buy Rating	23-08-11	MT
Oppenheimer Downgrades Marinus Pharmaceuticals to Perform From Outperform, Adjusts Price Target to $9 From $14	23-08-11	MT
Baird Adjusts Price Target on Marinus Pharmaceuticals to $20 From $24, Keeps Outperform Rating	23-08-11	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $20 From $21, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Truist Adjusts Price Target on Marinus Pharmaceuticals to $42 From $50, Keeps Buy Rating	23-05-12	MT
RBC Lowers Price Target on Marinus Pharmaceuticals to $21 From $22, Maintains Outperform, Speculative Risk	23-05-12	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $14 From $12, Maintains Outperform Rating	23-04-25	MT
JMP Securities Adjusts Price Target on Marinus Pharmaceuticals to $18 From $19, Maintains Market Outperform Rating	23-03-08	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $22 From $23, Maintains Outperform, Speculative Risk	23-03-08	MT
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating	23-01-23	MT
RBC Initiates Marinus Pharmaceuticals at Outperform, Speculative Risk, Sets Price Target at $23	23-01-20	MT
Baird Lowers Price Target on Marinus Pharmaceuticals to $24 From $32, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $12 From $23, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $23 From $28, Maintains Outperform Rating	22-08-12	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $28 From $32, Maintains Outperform Rating	22-05-16	MT
Cantor Fitzgerald Raises Marinus Pharmaceuticals Price Target to $28 From $25, Maintains Overweight Rating	22-04-20	MT
SVB Leerink Adjusts Marinus Pharmaceuticals' Price Target to $27 from $30, Keeps Outperform Rating	22-03-22	MT
JMP Securities Adjusts Marinus Pharmaceuticals' Price Target to $22 From $21, Keeps Market Outperform Rating	22-03-22	MT